An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).
BY Trine Alma Knudsen, M.D.
PUBLISHED June 21, 2018
Trine Alma Knudsen, M.D., a Ph.D. student in the department of hematology at the Zealand University Hospital in Roskilde, Denmark, discusses the DALIAH trial, which compared recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).
Initially, there was a higher percentage of patients in the interferon arm who stopped treatment due to toxicities. However, after about 18 months, the researchers saw that there wasn’t much difference between the two drugs. But according to other studies, Knudsen said, staying on interferon might be worth it, as it may prove to be the superior drug after a longer time on treatment.